PURPOSE: Nectin-4 is selectively overexpressed in a variety of cancers and is currently under clinical investigation as a therapeutic target. A monoclonal antibody against nectin-4 (AGS-22M6) was evaluated as an Immuno-positron emission tomography (ImmunoPET) reagent. Its ability to assay nectin-4 expression as well as detect nectin-4 positive tumors in the liver and bone was evaluated using mouse models. PROCEDURES: The biodistribution of [(89)Zr]AGS-22M6 was evaluated in mice bearing tumors with varying levels of nectin-4 expression. An isogenic breast cancer tumor line was used to model metastatic liver and bone disease in mice. The biodistribution of [(18)F]AGS-22M6 in cynomolgus monkeys was evaluated. RESULTS: A positive correlation was demonstrated between tumor nectin-4 expression and [(89)Zr]AGS-22M6 uptake. Tumors in the liver and bone were detected and differentiated based on nectin-4 expression. [(18)F]AGS-22M6 showed limited uptake in cynomolgus monkey tissues. CONCLUSIONS: [(89)Zr]AGS-22M6 is a promising ImmunoPET reagent that can assay nectin-4 expression in both primary and metastatic lesions.
PURPOSE:Nectin-4 is selectively overexpressed in a variety of cancers and is currently under clinical investigation as a therapeutic target. A monoclonal antibody against nectin-4 (AGS-22M6) was evaluated as an Immuno-positron emission tomography (ImmunoPET) reagent. Its ability to assay nectin-4 expression as well as detect nectin-4 positive tumors in the liver and bone was evaluated using mouse models. PROCEDURES: The biodistribution of [(89)Zr]AGS-22M6 was evaluated in mice bearing tumors with varying levels of nectin-4 expression. An isogenic breast cancer tumor line was used to model metastatic liver and bone disease in mice. The biodistribution of [(18)F]AGS-22M6 in cynomolgus monkeys was evaluated. RESULTS: A positive correlation was demonstrated between tumornectin-4 expression and [(89)Zr]AGS-22M6 uptake. Tumors in the liver and bone were detected and differentiated based on nectin-4 expression. [(18)F]AGS-22M6 showed limited uptake in cynomolgus monkey tissues. CONCLUSIONS: [(89)Zr]AGS-22M6 is a promising ImmunoPET reagent that can assay nectin-4 expression in both primary and metastatic lesions.
Entities:
Keywords:
ImmunoPET; Liver imaging; Nectin-4; Zr-89 PET
Authors: Thomas Wurdinger; Christian Badr; Lisa Pike; Ruben de Kleine; Ralph Weissleder; Xandra O Breakefield; Bakhos A Tannous Journal: Nat Methods Date: 2008-01-20 Impact factor: 28.547
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Volkan Beylergil; Serge Lyashchenko; Shutian Ruan; Stephen B Solomon; Jeremy C Durack; Jorge A Carrasquillo; Robert A Lefkowitz; Mithat Gonen; Jason S Lewis; Jason P Holland; Sarah M Cheal; Victor E Reuter; Joseph R Osborne; Massimo F Loda; Peter M Smith-Jones; Wolfgang A Weber; Neil H Bander; Howard I Scher; Michael J Morris; Steven M Larson Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-21 Impact factor: 9.236
Authors: Melissa S Derycke; Stefan E Pambuccian; C Blake Gilks; Steve E Kalloger; Abderrezak Ghidouche; Marc Lopez; Robin L Bliss; Melissa A Geller; Peter A Argenta; Katherine M Harrington; Amy P N Skubitz Journal: Am J Clin Pathol Date: 2010-11 Impact factor: 2.493
Authors: Scott M Knowles; Richard Tavaré; Kirstin A Zettlitz; Matthew M Rochefort; Felix B Salazar; Ziyue Karen Jiang; Robert E Reiter; Anna M Wu Journal: Clin Cancer Res Date: 2014-10-17 Impact factor: 12.531
Authors: C R Divgi; S Welt; M Kris; F X Real; S D Yeh; R Gralla; B Merchant; S Schweighart; M Unger; S M Larson Journal: J Natl Cancer Inst Date: 1991-01-16 Impact factor: 13.506
Authors: Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger Journal: Eur J Nucl Med Mol Imaging Date: 2008-05-09 Impact factor: 9.236